Launched in September, WHODrug Global Chinese meets increasing local and international regulatory requirements for the use of standardised drug data in clinical trials and drug safety monitoring.
The Chinese version of the dictionary includes information on drugs approved in China and makes all the data already contained in WHODrug Global available to users in their own language.
The bilingual drug referencing tool will simplify regulatory submissions in China by allowing users to code directly in Chinese. It also makes sure nothing gets lost in translation in other countries when submitting applications for drugs developed in China. Traditional medicines are widely used in the USA, for example, but with the FDA insisting that data from clinical studies is coded using WHODrug Global, more structured data is needed to gain future approvals.
Mao Söderberg, product specialist WHODrug Global Chinese, says the dictionary answers a pressing need both within and outside China for more consistent, quality-assured information. “Drug coding is tricky enough without having to translate back and forth between different languages,” she says. “The Chinese version of WHODrug Global solves that problem by allowing users to code in their native language with a standardised format for medicinal information. With WHODrug Global Chinese there is no room for inter-pretation.”
WHODrug Global Chinese is in the process of being rolled out in China, with WHODrug users receiving training and support through webinars, tutorials, and guidelines on how to use the dictionary in Chinese. The next training sessions will take place in Shanghai on November 11 and 13.